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   Clinical studies．． on PCr．904， a new broad ＄pectrum semisynthetic periicillin with high antipseudo－
monas activity， were carried out as follows．
   PC－904 wa’s administered to 20 cases of chronic urinary tract infectioris with drip infusion at the
dosa．ge of 1 to 4 g twice a day for a period of 4 to 8 days．
   Clinical effects were evaluated with “criteria for clinical evaluation of antimicrobial agents on
U． T． 1．”． Clipical efficacy rate was 200fi． in small dosage group （1 gftime），’600／．．in large dosage
group （more than 2 g／time）， and totally 400／．． ln thes6 cases， PC－904 was effective for the cases to
resist agalnst other various antibiotic therapies． But it was not efliective to patients’with an indwelting
catheter or low vital activities．
   As to the relation between the MIC and the eMcacy， it seεms to．be血ore e既ctivc to be treated
900 郡・ほか：慢性尿路感染症・PC－904
with more than 2 g of the PC－904．
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  第4群 その他の下部尿路感染症
 2種以上の原因菌を有する混合感染に対し，
  第5群 カテーテル留置群
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Table 2． Cjinical eMcacy of PC－9ca．
Case Age
































































































Renal stone ｛lx2） x 8
Bladder tumor （lx2） x 4
Prostatic hypertrophy ｛lx2） x 5
VesieoureteTal reflux （lx2） x 6
Renal stone Qx2｝ x 7
Hydronephrosis （lx2） x s
Prostatic hypertrophy ｛lx2） x 5
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Table 3． Overall clinical efficacy classified by type of infection．
Dosage Sπ［all dosaqe  （19／time） Large dosage （ 29／ti皿e｝
           ClinicalType of  fficacy infection
Lqo， of











3031                   3
P            2




2062                   2
H      2    3




一  曜  一  需 F 一  一  一 一  一 一  一
@  Sub total 7 工            6 14．3 10 1      4     5 50．0
唱ω×
・・h…叩（工O麗鈴・・hg・。・p暢n認1；t 02
1      1 50．0
Ol
1 ユ00．0
耐呂 ・H 一  一  一  一  一  一  一     一         一@  Sub total 2 1      1 50．0 1 1 100．0
Tota1 9 l     l      7 22．2 ll 2      4     5 54．4
Table 4． Bacteriological response．
Small dosage（1q／セime）f Larqedosaqe（2q／time）
工solated
     ■盾窒曹≠祉Gsms No． of  No． ofefficacyNo。of 翼O．ofefficacycaseson’b≠モ煤Feriuria cases onbac七eriuria
β． σoエゴ 2 1 4 ． 3
εeττa亡ia 3 1 4 1
Pエ「0亡eUS 4 2 0
PseロdomOηas1 0 0
Kエeわsゴeエエa 1 0 1 1
Glv（＝ 2 1 1 1
Gpc 0 2 2














Table 5．Sensitivity distributicn of isolated organism against PC－904．
                            8                          （10Vcells／ml）
工solated orqanis澱s 潤 I C （μ9／mユ）
≦6．25 ユ2．5≦～≦100    一                       ㎜ 100
8。 σ0エゴ 4 2
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